Investor relations
We are a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.
Press releases
Financial statements and public disclosure documents
| Year | Quarter | Date | Report | Download |
|---|---|---|---|---|
| 2021 | Q1 | March 1, 2021 | Interim Financial Statements | View PDF |
| 2021 | Q1 | March 1, 2021 | Management’s Discussion and Analysis | View PDF |
| 2020 | Q4 | December 31, 2020 | Filing Statement | View PDF |
| 2020 | Q4 | November 12, 2020 | Material Change Report | View PDF |
| 2020 | Q3 | July 3, 2020 | Material Change Report | View PDF |
Q1 • 2021
Q1 • 2021
Q4 • 2020
Q4 • 2020
Q3 • 2020
To view Novamind's full financial disclosures, please visit SEDAR
Advisors
Transfer agent
Marrelli Trust Company Limited
Legal Counsel
McMillan LLP
Auditor
DMCL LLP
Interested in investing? Contact IR@novamind.ca